Are γ-secretase inhibitors detrimental for Alzheimer's disease patients?

Article type: Short Communication

Authors: Ross, Joel S.^a | Imbimbo, Bruno P.^{b; *}

Affiliations: [a] Memory Enhancement Center, Eatontown, New Jersey, USA | [b] Chiesi Farmaceutici, Parma, Italy

Correspondence: [*] Correspondence: Dr. Bruno P. Imbimbo, Research and Development Department, Chiesi Farmaceutici, Via Palermo 26/A, 43100 Parma, Italy. Tel.: +39 0521 279278; Fax: +39 0521 279510, E-mail: b.imbimbo@chiesigroup.com.

Abstract: The recent failure of semagacestat in two large Phase III studies questions the value of γ-secretase inhibitors in treating Alzheimer's disease. Understanding the reasons of this setback may be important for the future research on effective treatments for this devastating disease.

DOI: 10.3233/JAD-2010-101548

Journal: Journal of Alzheimer's Disease, vol. 22, no. 2, pp. 401-404, 2010